Listen to Gynecologic Oncology

Editor's Choice:  FIGO 2023 staging may result in overtreatment of early-stage endometrial cancerEditorial: A path to precision in endometrial cancer management: Moving past FIGO 2023Hosted by: David Gaffney, MD, PhDThe University of Utah, Salt Lake City, Utah, United States of AmericaFeaturing: Allison Roy, MDSUNY Upstate Medical University, Syracuse, NY, United States of AmericaJessica N. McAlpineUniversity of British Columbia,  Vancouver, BC, CanadaDavid MutchWashington University School of Medicine, St Louis, MO, United States of AmericaCheck out more content on the journal's homepage  at https://www.gynecologiconcology-online.net

Editor's Choice:  Enhanced recovery after surgery (ERAS®) society guidelines for gynecologic oncology: 2026 updateEditorial: The evolving landscape of personalized perioperative care: A commentary on the 2026 ERAS® Gynecologic oncology guidelinesHosted by: Sean C. Dowdy, MD; Division of Gynecologic Oncology, Mayo Clinic College of Medicine, Rochester, MN, USAFeaturing: Gregg Nelson, MD, PhD; Department of Obstetrics & Gynecology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, CanadaRichard D. Urman, MD; Department of Anesthesiology, The Ohio State University Wexner Medical Center and College of Medicine, Columbus, OH, USAOlle Ljungqvist, MD, PhD; Department of Molecular Medicine & Surgery, Karolinska Institutet, Stockholm, SwedenCheck out more content on the journal's homepage  at https://www.gynecologiconcology-online.net

Editor's Choice:  Biomarker heterogeneity and efficacy of durvalumab plus carboplatin/paclitaxel followed by durvalumab with or without olaparib in patients with mismatch repair proficient endometrial cancer: exploratory analyses of the DUO-E/GOG-3041/ENGOT-EN10 trialEditorial: Hitting the mark—or missing it? The promise and peril of biomarkers in endometrial cancerHosted by: Amanda Nickles Fader, MD; Johns Hopkins Medicine Baltimore, MD, USAFeaturing: Kathleen Moore, MD; Gynecologic Cancer Clinic, Stephenson Cancer Center at the University of Oklahoma Medical Center, Oklahoma City, OK, USARamez N Eskander, MD;  Department of Obstetrics, Gynecology and Reproductive Sciences, Division of Gynecologic Oncology, UC San Diego, USACheck out more content on the journal's homepage  at https://www.gynecologiconcology-online.net

Editor's Choice:  Optimization of methylated DNA markers to rule out endometrial cancer in patients with abnormal uterine bleedingEditorial: Tampon-based methylated DNA testing for endometrial cancer: Promising innovation, but prudence before practiceHosted by: Charles N. Landen Jr., MD; University of Virginia Charlottesville, VA, USAFeaturing: Jamie N. Bakkum-Gamez, MD; Department of Obstetrics and Gynecology, Mayo Clinic, Rochester, MN, USAJohn B. Kisiel, MD; Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USAJoy M. Davis MD; Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USACheck out more content on the journal's homepage  at https://www.gynecologiconcology-online.net

Updates in US Food and Drug Administration approvals for poly-ADP-ribose polymerase inhibitors in Ovarian Cancer: A society of gynecologic oncology clinical practice reviewModerator:Ursula A. Matulonis, MD; Dana-Farber Cancer InstituteSpeakers:Bhavana Pothuri, MD; Perlmutter Cancer Center, NYU Langone HealthRóisín E. O’Cearbhaill, MD; Gynecologic Medical Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center; Department of Medicine, Weill Cornell Medical CollegeYvette Drew, MBBS, PhD; BC Cancer Centre Vancouver and University of British ColumbiaChristina Washington, MD; Stephenson Cancer Center, University of OklahomaUrsula A. Matulonis, MD, is joined by Bhavana Pothuri, MD, Róisín O’Cearbhaill, MD, Yvette Drew, MBBS, PhD, and Christina Washington, MD, to discuss recent updates in US Food and Drug Administration approvals for poly-ADP-ribose polymerase inhibitors (PARPi) in ovarian cancer. Based on the recent Society of Gynecologic Oncology clinical practice review published in Gynecologic Oncology, the speakers review the evolving role of PARP inhibitors and the clinical implications of updated regulatory approvals.The panel explores current evidence supporting PARP inhibitor use in ovarian cancer, including considerations for patient selection, biomarker testing, maintenance therapy, and safety considerations. The speakers also discuss how recent changes in FDA indications may affect clinical decision-making and treatment sequencing in practice.This podcast highlights practical clinical pearls to help guide practitioners in the appropriate integration of PARP inhibitors into the management of ovarian cancer patients.This podcast was developed by the Society of Gynecologic Oncology for Gynecologic Oncology.Check out more content on the journal's homepage  at https://www.gynecologiconcology-online.net

Editor's Choice:  Same day discharge after minimally invasive interval debulking surgery in advanced stage ovarian cancerEditorial: Same-day discharge in advanced ovarian cancer as a milestone of surgical evolution and patient selectionHosted by: Gregg Nelson, MD, PhD, FRCSC University of Calgary, Calgary, Alberta CanadaFeaturing: Surabhi Tewari, MD, Department of Obstetrics and Gynecology, Mass General Brigham, Harvard Medical School, Boston, MA, USAAlexander Melamed, MD MPH, Department of Obstetrics and Gynecology, Mass General Brigham, Harvard Medical School, Boston, MA, USAJose Alejandro Rauh-Hain, MD MPH, Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USACheck out more content on the journal's homepage  at https://www.gynecologiconcology-online.net

Editor’s Choice: Interstitial lung disease in targeted therapies: A Society of Gynecologic Oncology clinical practice statementHosted by:Jose Alejandro Rauh-Hain, MD MPHDepartment of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USAFeaturing:Charles A. Powell, MD, MBADivision of Pulmonary, Critical Care and Sleep Medicine, Tisch Cancer Center, Icahn School of Medicine at Mount Sinai, New York, NY, USACheck out more content on the journal's homepage  at https://www.gynecologiconcology-online.net

Editor's Choice:  Comparative outcomes of simple versus radical hysterectomy in patients with and without very low-risk early-stage cervical cancer: An exploratory analysis from the Gynecologic Cancer Intergroup/Canadian Cancer Trials Group CX.5/SHAPE trialEditorial: Commentary on: Comparative outcomes of simple versus radical hysterectomy in patients with and without very low-risk early-stage cervical cancer: An exploratory analysis from the Gynecologic Cancer Intergroup Canadian Cancer Trials Group Cx.5/SHAPE trialHosted by: Gregg Nelson, MD, PhD, FRCSC University of Calgary, Calgary, Alberta CanadaFeaturing: Janice S. Kwon  MD, MPH, FRCSC, University of British Columbia, Vancouver, Canada and  R. Wendel Naumann, MD Atrium Health, Wake Forest University School of Medicine, Charlotte, NC 28203, USACheck out more content on the journal's homepage  at https://www.gynecologiconcology-online.net

Editor’s Choice: Circulating tumor DNA monitoring in ovarian cancer patients receiving PARPi maintenance therapy: Can we further personalize treatment?Editorial: Towards personalizing PARP inhibitor maintenance therapy for ovarian cancerHosted by:Ursula Matulonis, MD, Associate Editor of Gynecologic OncologyFeaturing:Rebecca Arhend, University of Alabama at Birmingham, Birmingham, AL, USAChristina M. Annunziata, American Cancer Society, Atlanta, GA, USACheck out more content on the journal's homepage  at https://www.gynecologiconcology-online.net

Editor’s Choice: Reconsidering follow-up care in gynaecologic oncology: A scoping review exploring alternative approachesEditorial: Who is following up? Rethinking survivorship and surveillanceHosted by: Paola A Gehrig, MD University of Virginia Charlottesville, Virginia United StatesFeaturing:Lee-may Chen, MD; Division of Gynecologic Oncology, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, United StatesEsther Vermaas; Department of Obstetrics and Gynaecology, Division of Gynaecologic Oncology, Amsterdam UMC location Vrije Universiteit Amsterdam, Amsterdam, the NetherlandsJ.W.M. Aarts, MD, PhD; Principal Investigator and Gynaecological oncologist Amsterdam University Medical Centers, location VUMC, the NetherlandCheck out more content on the journal's homepage  at https://www.gynecologiconcology-online.net

Editor’s Choice: Ovarian cancer after breast cancer in women with a BRCA1 or BRCA2 pathogenic variantEditorial: Does a diagnosis of breast cancer reduce ovarian cancer risk in BRCA1/2 carriers:Why is this a question?Hosted by:John Farley, MD, COL(ret), FACOG, FACS, St Joseph's Hospital and Medical Center, Phoenix, AZ, United States of AmericaFeaturing:Steven Narod, Women's College Research Institute, University of Toronto, Toronto, Ontario, CanadaStephanie Blank, Icahn School of Medicine at Mount Sinai,  New York, NY, USAMelissa K. Frey, Weill Cornell Medicine, New York, NY, USACheck out more content on the journal's homepage  at https://www.gynecologiconcology-online.net

Editor’s Choice: A phase II, randomized, double-blind study of the use of rucaparib vs. placebo maintenance therapy in metastatic and recurrent endometrial cancerEditor’s Choice: Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FRα)–targeting antibody-drug conjugate (ADC), in combination with pembrolizumab in patients with platinum-resistant ovarian cancerEditorial: From one-size-fits all to biology-driven care: Emerging paradigms in gynecologic oncologyHosted by:Paola Gehrig, MD, Associate Editor of Gynecologic OncologyFeaturing:Bradley Corr, University of Colorado, Aurora, CO, USAUrsula Matulonis, Dana-Farber Cancer Institute, Boston, MA, USAMary M. Mullen, Washington University School of Medicine, St Louis, MO, USARebecca Arhend, University of Alabama at Birmingham, Birmingham, AL, USACheck out more content on the journal's homepage  at https://www.gynecologiconcology-online.net

Editor’s Choice: Surgical complexity and scope of procedures necessary after neoadjuvant chemotherapy for primary ovarian cancerHosted by:Ursula Matulonis, MD, Associate Editor of Gynecologic OncologyFeaturing:William Cliby, Department of Obstetrics and Gynecology, Mayo Clinic, Rochester, MN, USAChiara Ainio, Department of Obstetrics and Gynecology, Mayo Clinic, Rochester, MN, USAOliver Zivanovic, Clinic for Gynecology and Obstetrics, Heidelberg University Hospital, Heidelberg, GermanyCheck out more content on the journal's homepage  at https://www.gynecologiconcology-online.net

Editor’s Choice: Embracing and implementing the WHO cervical cancer elimination campaign goals: A consensus statement by SGO, ACOG, ASCCP, ASTRO, and ABS on minimum quality care standards for cervical cancer patients in the U.SEditorial: Health equity, disparities, and barriers to cervical cancer care in the U.S.: A consensus statement by SGO, ACOG, ASCCP, ASTRO, and ABS addressing the WHO cervical Cancer elimination campaign goals related to treatmentEditorial: Minimum standards for radiation therapy in the treatment of cervical cancer in the U.S.: A consensus statement by SGO, ASTRO, and ABS addressing the WHO Cervical Cancer Elimination Campaign goalsHosted by:Dr. Warner Huh, Associate Editor of Gynecologic OncologyFeaturing: Drs. Charles A. Leath, University of Alabama at Birmingham, Birmingham, AL, USA Junzo Chino, Duke University Medical Center, Durham, NC, USA Shane Neibart, Brigham and Women's Hospital, Boston, MA, USANancy Zhou, Rutgers New Jersey Medical School, Newark, NJ, USACheck out more content on the journal's homepage  at https://www.gynecologiconcology-online.net

Editor’s Choice: Integration of self-hypnosis in an enhanced recovery after surgery program in gynecologic oncology – A prospective randomized trialEditorial: Relax - It’s evidence-based: The role of hypnosis in managing post-operative symptomsHosted by:Jose Alejandro Rauh-Hain, MD, Associate Editor of Gynecologic OncologyFeaturing:Larissa Alejandra Meyer, Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, United StatesStacy D. D'Andre, Department of Oncology, Mayo Clinic, Rochester, MN, United StatesCheck out more content on the journal's homepage  at https://www.gynecologiconcology-online.net

Editor’s Choice: TROP2 expression and therapeutic targeting in uterine carcinosarcomaEditorial: The search for new therapeutic options for uterine carcinosarcomaHosted by:Amanda Nickles Fader, MD, Deputy Editor of Gynecologic OncologyFeaturing:Britta Weigelt, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USASara Moufarrij, Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USAKatherine Kurnit, Department of Obstetrics and Gynecology/Section of Gynecologic Oncology, The University of Chicago, Chicago, IL USACheck out more content on the journal's homepage  at https://www.gynecologiconcology-online.net

Editor’s Choice: STOMA study SToma-leak ratio in advanced ovarian cancer surgery: Results of a restrictive policy on the use of protective stoMAsEditorial: Diverting ileostomy: An ounce of prevention, but when?Hosted by:Diane Yamada, MD, Deputy Editor of Gynecologic OncologyFeaturing:Anna Fagotti, Department of Woman and Child Health and Public Health, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, ItalyVirginia Vargiu, Department of Woman and Child Health and Public Health, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, ItalyWilliam A. Cliby, MD, Division of Gynecologic Oncology, Mayo Clinic College of Medicine, Rochester, MN, USACheck out more content on the journal's homepage  at https://www.gynecologiconcology-online.net

Editor’s choice: A randomized phase II/III study of paclitaxel/carboplatin/metformin versus paclitaxel/carboplatin/placebo as initial therapy for measurable stage III or IVA, stage IVB, or recurrent endometrial cancer: An NRG Oncology/GOG studyEditorial: Rethinking metformin in advanced endometrial cancer: Scientific humility, translational challenges, and the urgency for equityHosted by:Sean Dowdy, MD, FACS, FACOG, Associate Editor of Gynecologic OncologyFeaturing:V.L. Bae-Jump, University of North Carolina at Chapel Hill, Chapel Hill, NC, USABrian M. Slomovitz, Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Mount Sinai Medical Center, Miami Beach, FLCheck out more content on the journal's homepage  at https://www.gynecologiconcology-online.net

Editor’s Choice: Platinum-free interval and response to platinum retreatment or lenvatinib/pembrolizumab in patients with recurrent endometrial cancer: A real-world endometrial cancer molecularly targeted therapy consortium cohort studyEditorial: Implications of the Platinum-Free Interval in Endometrial Cancer: A Legacy Worth Leaving Behind?Hosted by:Warner Huh, MD, Deputy Editor of Gynecologic OncologyFeaturing:Paulina Haight, Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, The Ohio State University Wexner Medical Center, James Hospital and Solove Research Institute, Columbus, OH, United States of AmericaRamez N. Eskander, MD, UC San Diego School of Medicine, Moores Cancer Center at UC San Diego Health, San Diego, CACheck out more content on the journal's homepage  at https://www.gynecologiconcology-online.net

Editor’s Choice: Primary prevention of post-molar gestational trophoblastic neoplasia in high-risk complete hydatidiform mole: A single-dose prophylactic actinomycin D, associated with uterine evacuation - a long retrospective cohort studyEditorial: Prevention of Gestational Trophoblastic Neoplasia with Actinomycin -D at the time of evacuation: A Matter of Routine Practice or Reserve for Special Circumstances?Hosted by:David Cohn, MD, MBA, FACHE, Editor-in-Chief of Gynecologic OncologyFeaturing:Elza Maria Hartmann Uberti, MD, Coordinator of the Center for Trophoblastic Diseases at Maternidade Mario Totta of Irmandade de Santa Casa de Misericórdia de Porto Alegre (ISCMPA), BrazilNeil S. Horowitz, MD, Division of Gynecologic Oncology, Department of Obstetrics, Gynecology, and Reproductive Biology Mass General Brigham, Harvard Medical School, Boston, MA, United StatesCheck out more content on the journal's homepage  at https://www.gynecologiconcology-online.net

Editor’s Choice: Clinical trial enrollment during first course of gynecologic cancer treatment and survivalEditorial: Clinical trials are not the solution to inequities in cancer careHosted by:Dr David Gaffney, MD, PhD, Associate Editor of Gynecologic OncologyFeaturing:Ashley Felix, PhD, MPH, Associate Professor, Division of Epidemiology. The Ohio State University College of Public HealthDavid Shalowitz, MD, MSHP, Director for Health Equity and Community Outreach. West Michigan Cancer CenterCheck out more content on the journal's homepage  at https://www.gynecologiconcology-online.net

Editor’s Choice: Characterizing the genomic landscape through the lens of FOLR1 status in low and high grade serous ovarian carcinomaEditorial: Following the folate receptor: Expanding targeted treatment options in low grade serous ovarian carcinomaHosted by:Warner Huh, MD, Deputy Editor of Gynecologic OncologyFeaturing:Tullia Rushton, MDBeryl L. Manning-Geist, MDCheck out more content on the journal's homepage  at https://www.gynecologiconcology-online.net

Editor’s Choice: The association of maintenance hormone therapy with overall survival in advanced-stage low-grade serous ovarian carcinoma: A risk-set matched retrospective studyEditorial: Hormonal maintenance therapy for advance low grade serous ovarian carcinoma appears to be of benefit – That's a relief!Hosted by:Ursula Matulonis, MD, Associate Editor of Gynecologic OncologyFeaturing:Alexander Melamed, MDJubilee Brown, MDCheck out more content on the journal's homepage  at https://www.gynecologiconcology-online.net

Editor’s Choice: Implementation of a financial navigation program in gynecologic oncologyEditorial: Financial toxicity: moving from describing the problem toward developing interventionsHosted by:Diane Yamada, MDFeaturing:Katharine M. Esselen, MDMargaret Liang, MDCheck out more content on the journal's homepage  at https://www.gynecologiconcology-online.net

Editor’s choice: The prognostic impact of substantial lymphovascular space invasion in women with node negative FIGO stage I uterine carcinomaEditorial: Is substantial lymphovascular space invasion in FIGO stage I endometrial carcinoma ready for primetime in deciding adjuvant treatment?Hosted by:Dr David Gaffney, MD, PhD, Associate Editor of Gynecologic OncologyFeaturing:Mohamed Elshaikh, MDBeriwal Sushil MDCheck out more content on the journal's homepage  at https://www.gynecologiconcology-online.net

Editor’s choice: Management of inguinal lymph nodes in locally advanced, surgically unresectable, squamous cell carcinoma of the vulvaEditorial: Optimizing and harmonizing lymph node dissection and radiotherapy in advanced vulvar cancerHosted by:Dr David Gaffney, MD, PhD, Associate Editor of Gynecologic OncologyFeaturing:Dr Lilian T. Gien, MD, MSc, FRCSC, University of Toronto, CanadaDr Brenna Swift, MD, FRCSC, MSc, MASc, University of Toronto, CanadaDr Scott Glaser, MD, City of Hope, USACheck out more content on the journal's homepage  at https://www.gynecologiconcology-online.net

Editor's Choice: 2023 FIGO staging system for endometrial cancer: The evolution of the revolutionEditorial: 2023 FIGO staging for endometrial cancer, a look at both sides of the coinHosted by:Sean Dowdy, MD, FACS, FACOG, Associate Editor of Gynecologic Oncology Featuring:Dr. Alexander Olawaiye, MD, University of Pittsburgh School of Medicine, USADr. David Gaffney, MD-PhD, University of Utah, USADr. Mario Leitao, Jr., MD, Memorial Sloan-Kettering Cancer Center, Weill Cornell Medical College, USACheck out more content on the journal's homepage  at https://www.gynecologiconcology-online.net

Editor’s choice: Shifting trends and sicker patients: Reassessing hysterectomy performed for benign indications by gynecologic oncologistsEditorial: Who you gonna call?Hosted by:David E. Cohn, MD, MBA, FACHE, Editor-in-Chief of Gynecologic OncologyFeaturing:M. Dwight Chen, MD, Palo Alto Foundation Medical Group/Sutter HealthConnor C. Wang, MD, Northwestern University Feinberg School of MedicineEmma Barber, MD, MS, Northwestern University Feinberg School of MedicineCheck out more content on the journal's homepage  at https://www.gynecologiconcology-online.net

Editor’s Choice: Identifying safe diagnostic algorithms for sentinel lymph node mapping in high-risk endometrial cancer: The SENTIREC-endo studyEditorial: Sentinel lymph node biopsy in high-risk endometrial cancer: The dénouementHosted by:Gregg Nelson, MD, Editor of Gynecologic OncologyFeaturing:Sarah M. Bjørnholt, MD, Aarhus University Hospital, DenmarkSean Dowdy, MD, Mayo Clinic, USACheck out more content on the journal's homepage  at https://www.gynecologiconcology-online.net

Editor’s Choice: Experiences of patients with peritoneal carcinomatosis-related complex care needs and their caregiversEditorial: The importance of family-focused care in the setting of advanced gynecological cancersHosted by:Sean Dowdy, MD, Associate Editor of Gynecologic OncologyFeaturing:Rachel A. Pozzar, PhD, RN, Dana Farber Cancer Institute and Harvard Medical SchoolAllison J. Applebaum, PhD, Caregivers Clinic, Memorial Sloan Kettering Cancer CenterCheck out more content on the journal's homepage  at https://www.gynecologiconcology-online.net

Editor’s Choice: Lunchbox trial: A randomized phase III trial of cisplatin and irradiation followed by carboplatin and paclitaxel versus sandwich therapy of carboplatin and paclitaxel followed by irradiation then carboplatin and paclitaxel for advanced endometrial carcinomaEditorial: What's in your “lunchbox”? Sandwich versus sequential chemotherapy and irradiation for advanced endometrial cancerHosted by:Ursula Matulonis, MD, Associate Editor of Gynecologic OncologyFeaturing:Joyce Barlin, MD, Women’s Cancer Care Associates & Albany Medical CollegeGretchen Glaser, MD, Mayo Clinic John Weroha, MD, Mayo ClinicCheck out more content on the journal's homepage  at https://www.gynecologiconcology-online.net

Editor’s Choice: Associations between modifiable lifestyle factors and health-related quality of life among endometrial carcinoma survivors - A cross-sectional studyEditorial: Optimising endometrial cancer survivorship through lifestyle changeHosted by:Gregg Nelson, MD, PhD, Social Media Editor of Gynecologic OncologyFeaturing:Ane Gerda Z. Eriksson, MD, Oslo University Hospital, Norway S. J. Kitson, MD, University of Manchester, UKCheck out more content on the journal's homepage  at https://www.gynecologiconcology-online.net

Editor’s Choice: Use of a mobile health patient engagement technology improves perioperative outcomes in gynecologic oncology patientsEditorial: How does mobile health engagement technology help gynecologic oncology patients recover from surgery, affect health equity, and impact healthcare costs?Hosted by:Gregg Nelson, MD, PhD, Social Media Editor of Gynecologic OncologyFeaturing:Teresa K.L. Boitano, MD, University of Alabama at BirminghamKevin M. Elias, MD, FACOG, FACS, Brigham and Women’s HospitalCheck out more content on the journal's homepage  at https://www.gynecologiconcology-online.net

Editor’s Choice: Overall survival and patient-reported outcome results from the placebo-controlled randomized phase III IMagyn050/GOG 3015/ENGOT-OV39 trial of atezolizumab for newly diagnosed stage III/IV ovarian cancerHosted by:Ursula Matulonis, MD, Associate Editor of Gynecologic OncologyFeaturing:Kathleen N. Moore, MD, GOG-F and Stephenson Cancer Center at the University of Oklahoma Health Sciences Center Check out more content on the journal's homepage  at https://www.gynecologiconcology-online.net

Editor’s Choice: Incidence of venous thromboembolism in patients with advanced stage ovarian cancer undergoing neoadjuvant chemotherapy: Is it time for thromboprophylaxis?Editorial: Universal thromboprophylaxis in ovarian cancer patients before and after surgery?Hosted by:David E. Cohn, MD, MBA, FACHE, Editor-in-Chief of Gynecologic OncologyFeaturing:Amanika Kumar, MD, Mayo Clinic Laura Havrilesky, MD, Duke University Check out more content on the journal's homepage  at https://www.gynecologiconcology-online.net

Editor’s Choice: Improving genetic testing following abnormal mismatch repair immunohistochemistry results in endometrial cancerEditorial: Universal testing – Should it be that hard? Probably. If you're doing it rightHosted by:Gregg Nelson, MD, PhD, Editor of Gynecologic OncologyFeaturing:Bhavana Pothuri, MD, NYU Perlmutter Cancer CenterLeigha Senter, MS, CGC, The Ohio State University College of MedicineCheck out more content on the journal's homepage  at https://www.gynecologiconcology-online.net

Editor’s Choice: Detection of endometrial cancer using tampon-based collection and methylated DNA markersEditorial: Early detection of endometrial cancerHosted by:Dineo Khabele, MD, Associate Editor of Gynecologic OncologyFeaturing:Jamie N. Bakkum-Gamez, MD, Mayo ClinicJonathan C. Dudley, MD, The Johns Hopkins University School of MedicineCheck out more content on the journal's homepage  at https://www.gynecologiconcology-online.net

Tyrosine kinase inhibitor toxicities: A society of gynecologic oncology review and recommendationsHosted by:Róisín O’Cearbhaill, MD, Gynecologic Medical Oncologist, Memorial Sloan Kettering Cancer Center, New YorkFeaturing:BJ Rimel, MD, Gynecologic Oncologist, Cedars-Sinai Medical CenterErin Crane, MD, MPH, Gynecologic Oncologist, Levine Cancer InstituteVicky Makker, MD, Medical Oncologist, Memorial Sloan Kettering Cancer CenterJennifer MacDonald, PharmD, Oncology Clinical Pharmacy Specialist, Medical University of South CarolinaRóisín O’Cearbhaill, MD, is joined by BJ Rimel, MD, Erin Crane, MD, MPH, Vicky Makker, MD, and Jennifer McDonald, PharmD, to review the clinical management of tyrosine kinase inhibitors (TKIs) in gynecologic cancers with consideration for dose adjustments and modifications. The speakers discuss the optimal management of commonly encountered toxicities, such as hypertension and hypothyroidism, that are associated with several of the TKIs.They also highlight management strategies, patient reference materials and anticipatory prescriptions for antihypertensives, antidiarrheals, and antiemetics. The podcast includes two patient cases that delve into information about the differences in toxicities between lenvatinib and pazopanib, hypertension and which drugs to use in which order (both starting dose and dose adjustments), and medical access and lab intervals. These practical clinical pearls in managing toxicities aim to guide practitioners on how best to use these drugs to treat gynecologic cancers.This podcast was developed by the Society of Gynecologic Oncology for Gynecologic Oncology.Check out more content on the journal's homepage  at https://www.gynecologiconcology-online.net

Editor’s Choice: Enhanced recovery after surgery (ERAS®) society guidelines for gynecologic oncology: Addressing implementation challenges - 2023 updateEditorial:  Gynecologic oncology surgery – Ready for the next step in ERASHosted by:Amanda Nickles Fader, MD, Editor of Gynecologic OncologyFeaturing:Gregg Nelson, MD, PhD, University of CalgarySean Dowdy, MD, Mayo Clinic College of MedicineOlle Ljungqvist, MD, Örebro University HospitalCheck out more content on the journal's homepage  at https://www.gynecologiconcology-online.net

Editor’s Choice: What's in it for me?: A value assessment of gynecologic cancer clinical trials for Black womenEditorial:  Achieving diversity in clinical trial enrollment by reducing burden and increasing value: A patient-centered approachHosted by:Ursula Matulonis, MD, Associate Editor of Gynecologic OncologyFeaturing:Ann Oluloro, MD, MPH, University of WashingtonEloise Chapman-Davis, MD, Weill Cornell MedicineCheck out more content on the journal's homepage  at https://www.gynecologiconcology-online.net

Editor’s Choice: Doubling down on the future of gynecologic oncology: The SGO future of the profession summit reportEditorial:  “The times they are a-changin’” – And how are we managing?Hosted by:David E. Cohn, MD, MBA, FACHE, Editor-in-Chief of Gynecologic OncologyFeaturing:Stephanie V. Blank, MD, Icahn School of Medicine at Mount SinaiWarner K. Huh, MD, FACOG, FACS, University of Alabama BirminghamCheck out more content on the journal's homepage  at https://www.gynecologiconcology-online.net

Editor’s Choice: Intrathoracic surgery as part of primary cytoreduction for advanced ovarian cancer: Going to the next level – A Memorial Sloan Kettering Cancer Center studyEditorial: Intrathoracic surgery as part of primary cytoreduction for advanced ovarian cancer: The evolution of a “pelvic” surgeonHosted by:Warner K. Huh, MD, FACOG, FACS, Deputy Editor of  Gynecologic OncologyFeaturing:Ryan M. Kahn MD,FACOG, Memorial Sloan Kettering Cancer CenterDennis Chi, MD, Memorial Sloan Kettering Cancer CenterProf Christina Fotopoulou, Imperial College London, UKCheck out more content on the journal's homepage  at https://www.gynecologiconcology-online.net

Editor’s Choice: Cervical cancer geographical burden analyzer: An interactive, open-access tool for understanding geographical disease burden in patients with recurrent or metastatic cervical cancerEditorial: Targeting our efforts: the contribution of an open-access tool to assess geographic distribution of recurrent and metastatic cervical cancerHosted by:Wendy R. Brewster, MD, PhD, Deputy Editor of Gynecologic OncologyFeaturing:Turgay Ayer, Georgia Institute of TechnologyTara Castellano, MD, Louisiana State University HSCIsabel C. Scarinci, PhD, MPH, University of Alabama at BirminghamCheck out more content on the journal's homepage  at https://www.gynecologiconcology-online.net

Molecular testing for endometrial cancer: An SGO clinical practice statementHosted by: Kari Hacker, MD, PhD, Gynecologic Oncologist, New York University Langone Health Featuring: Christine Walsh, MD, MS, Gynecologic Oncologist, University of ColoradoCarolyn McCourt, MD, Gynecologic Oncologist, Washington University School of MedicineKari Hacker, MD, PhD, is joined by Christine Walsh, MD, MS, and Carolyn McCourt, MD, to review basic molecular classification as well as more complex biomarkers in endometrial cancer. They discuss how testing can be utilized to inform patient prognosis and to guide second line systemic treatment decisions. They also highlight several ongoing trials investigating treatment strategies based on molecular features, the results of which will help clinicians make better therapeutic decisions, resulting in better outcomes for patients with endometrial cancer. This podcast was developed by the Society of Gynecologic Oncology for Gynecologic Oncology.Check out more content on the journal's homepage  at https://www.gynecologiconcology-online.net

Editor’s Choice: Sentinel lymph node mapping in patients with endometrial hyperplasia: A practice to preserve or abandon?Editor’s Choice: Is sentinel lymph node assessment useful in patients with a preoperative diagnosis of endometrial intraepithelial neoplasia?Editorial: Routine SLN biopsy for endometrial intraepithelial neoplasia: A pragmatic approach or over-treatment?Hosted by:Gregg Nelson, MD, PhD, Editor of Gynecologic OncologyFeaturing:Jennifer Mueller MD, Memorial Sloan Kettering Cancer CenterEmad Matanes MD, Rambam Medical CenterEmma Rossi MD, Duke University Medical CenterCheck out more content on the journal's homepage  at https://www.gynecologiconcology-online.net

Article: SGO and the elephant that is still in the room: Wellness, burnout and gynecologic oncologyHosted by:Gregg Nelson, MD, PhD, Editor of Gynecologic OncologyFeaturing:Brittany A. Davidson, MD, Duke UniversityDavid M. Kushner, MD, UW School of Medicine and Public HealthCheck out more content on the journal's homepage  at https://www.gynecologiconcology-online.net

Editor’s Choice: Clinical and molecular characteristics of ARIEL3 patients who derived exceptional benefit from rucaparib maintenance treatment for high-grade ovarian carcinomaEditorial: The rapid evolution of PARP inhibitor therapy for advanced ovarian cancer: Lessons being learned and new questions emerging from phase 3 trial long-term outcome dataHosted by: Ursula Matulonis, MD, Associate Editor of Gynecologic Oncology and Author of the editorialFeaturing: David O'Malley, MD, The Ohio State UniversityCheck out more content on the journal's homepage  at https://www.gynecologiconcology-online.net

Editor’s Choice: Contemporary primary treatment of women with stage II-IV low-grade serous ovarian/peritoneal cancer (LGSOC): Determinants of relapse and disease-free survivalEditorial: Low grade serous ovarian cancer: Unpicking drivers of outcomeHosted by: Amanda Nickles Fader, MD, Associate Editor of Gynecologic OncologyFeaturing:David M. Gershenson, MD, The University of Texas MD Anderson Cancer CenterCharlie Gourley, MD, Nicola Murray Centre for Ovarian Cancer ResearchCheck out more content on the journal's homepage  at https://www.gynecologiconcology-online.net

Editor’s Choice: Unilateral inguinofemoral lymphadenectomy in patients with early-stage vulvar squamous cell carcinoma and a unilateral metastatic sentinel lymph node is safeEditorial: When is it safe to omit contralateral groin management in unilateral sentinel node-positive early stage vulvar cancer?Hosted by: S. Diane Yamada, MD, Deputy Editor of Gynecologic OncologyFeaturing:Maaike Oonk, MD, University Medical Center Groningen, University of Groningen, The NetherlandsAkila Viswanathan, MD, MPH, Johns Hopkins MedicineCheck out more content on the journal's homepage  at https://www.gynecologiconcology-online.net

Editor’s Choice: Preoperative assessment using the five-factor modified frailty index: A call for standardized preoperative assessment and prehabilitation services in gynecologic oncologyEditorial: Answering the call: Are we ready for action on frailty in gynecologic oncology?Hosted by:Gregg Nelson, MD, PhD, Social Media Editor of Gynecologic OncologyFeaturing:Mariam M. AlHilli, MD Gynecologic Oncologist, Cleveland Clinic, Cleveland, OhioAmanika Kumar, MD, Mayo Clinic Division of Gynecologic Surgery, Rochester, MinnesotaCheck out more content on the journal's homepage  at https://www.gynecologiconcology-online.net